Glofitamab with chemoimmunotherapy for HIV-related large b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called glofitamab combined with standard chemoimmunotherapy (called R-CHOP) for people with HIV-related large B-cell lymphoma that has not been treated before. The goal is to see if adding this drug improves outcomes and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have HIV and be taking anti-HIV medications (antiretroviral therapy).
- You must have a type of lymphoma that is 'large B-cell lymphoma' and tests positive for a marker called CD20.
- You must have stage II, III, or IV disease that can be measured (e.g., enlarged lymph nodes or lesions).
- You must have adequate organ function, such as acceptable blood counts, liver, kidney, and heart function.
- You must be willing to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial tests adding a new immunotherapy drug called glofitamab to standard chemotherapy for aggressive lymphomas. The goal is to see if the combination is more effective at shrinking or eliminating the lymphoma.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
Hear when a new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.